Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Bailey

Emergency Medicine Pittsburgh, PA Doctor of Osteopathy

NPI 1184612863 CMS profile 823826

4800 Friendship Ave, Emerg Med Western Penna Hospital, Pittsburgh, PA 15224

Open in the dashboard

General payments

$2,457

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Bailey of Pittsburgh, PA is reported in the CMS Open Payments database as having received $2,457 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $378 18
2024 General $488 23
2023 General $566 27
2022 General $276 14
2021 General $360 20
2020 General $200 11
2019 General $189 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Bailey
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to William Bailey were reported at $378. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year William Bailey Emergency Medicine median Middle half National median
2019 $189 $51 $18–$128 $163
2020 $200 $29 $16–$99 $114
2021 $360 $40 $18–$124 $132
2022 $276 $49 $20–$134 $149
2023 $566 $51 $22–$142 $160
2024 $488 $52 $22–$150 $164
2025 $378 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $569 28 payments
  2. Janssen Pharmaceuticals, Inc $448 25 payments
  3. E.R. Squibb & Sons, L.L.C. $413 21 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $243 11 payments
  5. Scpharmaceuticals Inc. $235 13 payments
  6. Kestra Medical Technology Services, Inc. $138 5 payments
  7. Novartis Pharmaceuticals Corporation $97 5 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $60 3 payments
  9. Merck Sharp & Dohme Corporation $54 3 payments
  10. Amgen Inc. $52 2 payments
  11. Other $148 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,457 124 payments
Products named General payments · program years 2019–2025
  1. VYNDAQEL $539 26 payments
  2. XARELTO $448 25 payments
  3. FUROSCIX $235 13 payments
  4. ELIQUIS Cardiovascular $233 12 payments
  5. CAMZYOS $180 9 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $152 9 payments
  7. JARDIANCE $137 6 payments
  8. Assure WCD $105 4 payments
  9. ENTRESTO $97 5 payments
  10. SPIRIVA RESPIMAT $61 3 payments
  11. Other $447 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$64,435

Medicare's payments for the services billed

Medicare patients

299

Average age 76

Services billed

729

159 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 49%
Heart failure 48%
Diabetes 45%
Atrial fibrillation 41%
Chronic kidney disease 38%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $123
$123 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $93
$93 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $74
$74 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $19
$19 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record